Øystein Soug, CEO of Targovax ASA, has through Abakus Invest AS on 9 July 2019 acquired 10,000 shares in Targovax ASA at a price of NOK 6.690 per share. Following the transaction, Øystein Soug and his close associates hold 200,000 shares and 1,160,000 options in Targovax ASA.
Torbjørn Furuseth, CFO of Targovax ASA, has on 9 July 2019 acquired 15,000 shares in Targovax ASA at a price of NOK 6.693 per share. Following the transaction, Torbjørn Furuseth and his close associates hold 15,000 shares and 300,000 options in Targovax ASA.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It activates the immune system to generate tumor-specific immune responses. In a phase I monotherapy trial, ONCOS-102 induced both local and systemic innate and adaptive immune activation, with associated clinical benefit. In an ongoing phase I trial, patients who have progressed on anti-PD1 checkpoint inhibitors and treated with ONCOS-102 in combination with Keytruda, demonstrated responses in three of nine patients (33% ORR) including one complete response. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase I/II trial expected to report around new year 2019-20.